Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory polyarthritis with increased mortality largely attributable to cardiovascular disease. There is extensive evidence that patients with RA experience accelerated atherosclerosis, which is considered as the main responsible of this increased cardiovascular burden. Nowadays atherosclerosis is regarded as an inflammatory condition: hence, the cumulative inflammation of RA, with the abundant synthesis of proinflammatory cytokines, contributes directly to the early formation of the atheromatic plaque. It is therefore reasonable to postulate that, by alleviating inflammation, drugs commonly used in RA treatment may ameliorate the cardiovascular profile of these patients. Here we provide an extensive review of the literature, focusing on the effects of the available anti-rheumatic agents on cardiovascular mortality, and morbidity among RA sufferers.
Keywords: Rheumatoid arthritis, cardiovascular disease, atherosclerosis, inflammation, DMARDs, anti-TNF-α agents, novel biologic agents, atheromatic plaque, AMI, cytokines
Current Vascular Pharmacology
Title:Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis
Volume: 10 Issue: 5
Author(s): Cecilia Chighizola, Tommaso Schioppo, Francesca Ingegnoli and Pier Luigi Meroni
Affiliation:
Keywords: Rheumatoid arthritis, cardiovascular disease, atherosclerosis, inflammation, DMARDs, anti-TNF-α agents, novel biologic agents, atheromatic plaque, AMI, cytokines
Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory polyarthritis with increased mortality largely attributable to cardiovascular disease. There is extensive evidence that patients with RA experience accelerated atherosclerosis, which is considered as the main responsible of this increased cardiovascular burden. Nowadays atherosclerosis is regarded as an inflammatory condition: hence, the cumulative inflammation of RA, with the abundant synthesis of proinflammatory cytokines, contributes directly to the early formation of the atheromatic plaque. It is therefore reasonable to postulate that, by alleviating inflammation, drugs commonly used in RA treatment may ameliorate the cardiovascular profile of these patients. Here we provide an extensive review of the literature, focusing on the effects of the available anti-rheumatic agents on cardiovascular mortality, and morbidity among RA sufferers.
Export Options
About this article
Cite this article as:
Chighizola Cecilia, Schioppo Tommaso, Ingegnoli Francesca and Luigi Meroni Pier, Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis, Current Vascular Pharmacology 2012; 10 (5) . https://dx.doi.org/10.2174/157016112801784503
DOI https://dx.doi.org/10.2174/157016112801784503 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis
Current Vascular Pharmacology Oxidative Stress and the Use of Antioxidants for the Treatment of Rheumatoid Arthritis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Role of Cytokines and Matrix Metallo-Proteinases in Patients with Temporo- Mandibular Joint Internal Derangements and/or Osteoarthritis
Recent Patents on Biomarkers Lipid Peroxidation End-Products as Modulators of Catabolic and Inflammatory Responses in Arthritis: A Review
Current Rheumatology Reviews The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19
Recent Patents on Anti-Infective Drug Discovery Molecular Mechanisms of Drug Photodegradation and Photosensitization
Current Pharmaceutical Design Preparation and Characterization of Sulphasalazine Loaded Nanoparticles by Nanoprecipitation and Ionotropic Gelation Techniques Using Various Polymers
Current Nanomedicine New Molecules as Drug Candidates for the Treatment of Upper and Lower GI Tract Ulcers
Current Pharmaceutical Design Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Current Drug Metabolism Study of Intercellular Adhesion Molecule-1 (ICAM-1) in Bone Homeostasis
Current Drug Targets RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Prostanoid Receptors as Possible Targets for Anti-Allergic Drugs: Recent Advances in Prostanoids on Allergy and Immunology
Current Drug Targets Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry Connexins in Renal Endothelial Function and Dysfunction
Cardiovascular & Hematological Disorders-Drug Targets Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Assorted Applications of N-substituted-2,4-thiazolidinediones in Various Pathological Conditions
Mini-Reviews in Medicinal Chemistry Sepsis: Links between Pathogen Sensing and Organ Damage
Current Pharmaceutical Design